Production of Monoclonal Antibodies
The discovery of monoclonal antibodies (mAbs) produced by “hybridoma technology” by George Köhler and Cesar Milstein in 1975 has had a great impact both on basic biological research and on clinical medicine. However, this impact was not immediately recognized. It took around 10 years to appreciate the importance of using these mAbs in various fields of science other than immunology, such as cell biology, biochemistry, microbiology, virology, para-sitology, physiology, genetics, and molecular biology; and also in areas of clinical medicine, such as pathology, hematology, oncology, and infectious disease. The contribution of mAbs to science and clinical medicine was recognized in 1984 by the award of the Nobel Prize for Medicine to Köhler and Milstein.
KeywordsSpleen Cell Myeloma Cell Counting Chamber Salvage Pathway Myeloma Cell Line
- Goding, J. W., ed. (1996) Monoclonal Antibodies: Principles and Practice: Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology, 3rd ed., Academic, New York.Google Scholar
- Ritter, M. A. and Ladyman, H. M., eds. (1995) Monoclonal Antibodies: Production, Engineering, and Clinical Application, Cambridge University Press, Cambridge, UK.Google Scholar
- Springer, T. A., ed. (1985) Hybridoma Technology in the Biosciences and Medicine, Plenum, New York.Google Scholar
- McMichael, A. J. and Fabre, J. W., ed. (1982) Monoclonal Antibodies in Clinical Medicine, Academic, New York.Google Scholar